Investors should consider putting money in this pharmaceutical stock poised to rally as it offers more clarity on its epilepsy drug, Goldman Sachs says.
Investors should consider putting money in Xenon Pharmaceuticals , a biopharma stock poised to rally as Wall Street gains more clarity on its drug to treat epilepsy, Goldman Sachs says. Analyst Paul Choi initiated coverage of Xenon with a buy rating and a $60 price target, saying in a note to clients Thursday that investors are underestimating the opportunities that could come from the rollout of XEN1101 — a treatment for focal onset seizures commonly experienced by people with epilepsy.
" Those gains would come even after a solid 24% gain this year and near 8% gain this month." In 2015, about 1.2% of the U.S. population, or about 3.4 million people, were diagnosed with epilepsy , according to the Centers for Disease Control and Prevention. XEN110 is being developed for the treatment of major depressive disorders, generalized tonic-clonic seizures and other neurological disorders, which could drive further value for the company going forward.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Goldman Sachs names Boeing its top aerospace stock, says orders should increase as air travel reboundsThe need for new, fuel-efficient aircraft to meet resurgent demand should benefit Boeing, Goldman says.
Lire la suite »
Goldman Sachs downgrades Western Digital, says stock can tumble nearly 15% in memory industry downturnA looming downturn in the memory industry makes now a good time to sell shares of Western Digital, according to Goldman Sachs
Lire la suite »
Goldman Sachs may slash bonuses for investment bankers by 40%: reportIf implemented, the cuts would be the steepest since the 2008 financial crisis.
Lire la suite »
BoE Preview: Bank will opt for further hikes in the first half of 2023 – Goldman SachsGurpreet Gill, Macro Strategist, Global Fixed Income, Goldman Sachs Asset Management, expresses his view on the likely Bank of England (BoE) monetary
Lire la suite »
Goldman Sachs names 3 'conviction list' stocks that could profit from their efforts to go greenGoldman Sachs reveals part of its conviction list — companies investing in sustainability that are showing 'attractive corporate returns.'
Lire la suite »
Gold is better portfolio diversifier than bitcoin – Goldman SachsGoldman Sachs expects gold, with its real demand drivers, to outperform the highly volatile bitcoin in the long term, the bank wrote in a Monday research note. gold bitcoin
Lire la suite »